Unleashing the biomimetic targeting potential of platelet-derived nanocarriers on atherosclerosis.

Atherosclerosis, the primary mechanism underlying the development of many cardiovascular illnesses, continues to be one of the leading causes of mortality worldwide. Platelet (PLT), which are essential for maintaining body homeostasis, have been strongly linked to the onset of atherosclerosis at various stages due to their inherent tendency to bind to atherosclerotic lesions and show an affinity for plaques. Therefore, mimicking PLT's innate adhesive features may be necessary to effectively target plaques. PLT-derived nanocarriers have emerged as a promising biomimetic targeting strategy for treating atherosclerosis due to their numerous advantages. These advantages include excellent biocompatibility, minimal macrophage phagocytosis, prolonged circulation time, targeting capability for impaired vascular sites, and suitability as carriers for anti-atherosclerotic drugs. Herein, we discuss the role of PLT in atherogenesis and propose the design of nanocarriers based on PLT-membrane coating and PLT-derived vesicles. These nanocarriers can target multiple biological elements relevant to plaque development. The review also emphasizes the current challenges and future research directions for the effective utilization of PLT-derived nanocarriers in treating atherosclerosis. [Display omitted] • Role of platelet in atherogenesis. • Mimicking platelet innate adhesive features that are necessary to effectively target plaques. • Synthesis of platelet membrane-coated nanoparticles and their application in atheroscelrosis. • Synthesis of platelet-derived nanovesicles and their application in atheroscelrosis. • Current challenges and future research directions for the effective use of platelet-derived nanocarriers for atherosclerosis. [ABSTRACT FROM AUTHOR]